Eleven Bio. gibts hier was zu holen?

Eleven Biotherapeutics to Report Second Quarter 2017 Financial Results on Monday, August 14, 2017 and provide a corporate update..

http://ir.elevenbio.com/releasedetail.cfm?ReleaseID=1036232

Na schaue ma mal...  

newbie-evo wie ist deine meinung zu Eleven  

gespalten...
momentan wieder etwas positiver gestimmt ;-)

http://www.businesswire.com/news/home/20170814005384/en/
 

...Analysts have placed a $12 price target on Eleven Biotherapeutics, Inc...

http://www.postanalyst.com/2017/08/14/...rapeutics-incorporated-cort/

Na... wers glaubt
 

Hat einer eine Meinung?  

meiner Meinung nach, ist es so, dass mehr Leute die Aktie verkaufen, als Andere die kaufen wollen...

*Achtung* ist eine sehr gewagte Theorie  ;-)

 

 Angesichts der Begeisterung von Eleven für die schnelle Entwicklung der Vicinium-Entwicklung, konzentriert sich das Unternehmen auf die fortgesetzte Weiterentwicklung seiner Phase-3-Zulassungsstudie zu diesem Zeitpunkt und behält vorübergehend die Entwicklung seiner früheren Produktkandidaten, Proxinium und VB6-845d. Das Unternehmen freut sich darauf, diese zu gegebener Zeit weiterzuleiten.

Es geht bei der Übersetzung unter, das die anderen Forschungszweige eingefroren werden und das Augenmerk auf dieses Produkt konzentriert wird.
 

Was ist los (NEWS ?)  

Buyout Roche $12.00 to $20.00.. ?

https://stocktwits.com/symbol/EBIO

Auf Stocktwits wird spekuliert über einen Buyout... das dient wohl z.Z. als Kurstreiber.

Na mal schauen..
Glauben kann ja bekanntlicherweise Berge versetzen ;-)  

newbie-evo  vieleicht eine übernahme ?? zu diesen Preisen  

ob buyout oder Übernahme...

mir egal, solange der Aktienpreis bei 12..20 $ landet *grins*

Denke aber, das ist eine sehr weit hergeholte Spekulation..
Aber möglich wäre es schon ;-)  

Was soll ich machen geht es noch höher oder halten  

Ich würde jedem Investierten den Buyout gönnen, habe aber Zweifel, dass dieser auch kommt.
Laut den letzten Zahlen reicht das Geld nicht mehr lange, so dass gerade auch ein Hochziehen vor einer Kapitalerhöhung stattfinden könnte.
War bei Blrx im März ähnlich.
Also vorsichtig sein!

 

Eleven Biotherapeutics Appoints Richard Fitzgerald as Interim Chief Financial Officer
October 13, 2017
-- Brings extensive capital raising and transaction experience to Eleven’s management team --
CAMBRIDGE, Mass.
--(BUSINESS WIRE)--Oct. 13, 2017--
Eleven Biotherapeutics, Inc.
(NASDAQ:EBIO), a late-stage clinical oncology company advancing novel
product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today announced the appointment of
Richard F. Fitzgerald
as Interim Chief
Financial Officer effective
October 20, 2017
.
John McCabe
, who currently holds that position, will be stepping down.
“We are pleased to welcome Richard to the management team at Eleven. He brings significant experience in capital raising and strategic leadership to the
company, as we look forward to top-line three-month data from our Phase 3 trial of our lead drug candidate Vicinium in mid-2018,” said Stephen Hurly, Chief
Executive Officer of
Eleven Biotherapeutics
. “We thank
John McCabe
for his many contributions as CFO, particularly his execution of the Viventia Bio integration
following our 2016 merger.”
“I am excited to be joining the leadership team at Eleven at such an exciting time for the company. Our targeted protein therapeutics platform continues to be a
novel and productive source of innovative drug candidates, including Vicinium, which has the potential to be a therapeutic option for patients with BCG-refractory
non-muscle invasive bladder cancer,” said Mr. Fitzgerald. “I look forward to helping the company execute its financial and strategic plan and drive value for its
shareholders.”
Mr. Fitzgerald brings over two decades of financial and strategic leadership to
Eleven Biotherapeutics
. Most recently, he served as a consultant to private life
science based companies from
July 2017
through
October 2017
. Before that, Mr. Fitzgerald served as Chief Financial officer of
Pavmed Inc.
, where he completed
its IPO in
April 2016
. He previously served as Chief Financial Officer at
Techprecision Corporation
and
Nucleonics Inc.
, and in several financial and business
development positions of increasing responsibility at
Exelon Corporation
. He holds his B.S. in Business Administration from
Bucknell University
.
About
Eleven Biotherapeutics
:
Eleven Biotherapeutics, Inc.
is a late-stage, clinical oncology company advancing novel product candidates based upon the Company’s targeted protein
therapeutics (TPTs) platform. The Company’s TPTs incorporate a tumor-targeting antibody fragment and a protein cytotoxic payload into a single protein molecule
in order to achieve focused tumor cell killing. The Company believes its TPT approach offers significant advantages in treating cancer over existing antibody drug
conjugate technologies. The Company believes its TPTs provide effective tumor targeting with broader cancer cell-killing properties than are achievable with small
molecule payloads that require tumor cell proliferation and face multi-drug resistant mechanisms. Additionally, the Company believes that its TPT’s cancer cell-
killing properties promote an anti-tumor immune response that will potentially combine well with immune oncology drugs such as checkpoint inhibitors. For more
information, please refer to the Company’s website at
 

The new CFO has great experience in mergers and acquisitions.  

Eleven Biotherapeutics, Inc. (“Eleven” or the “Company”) (EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today announced the pricing of an underwritten public offering of 5,525,000 shares of its common stock, pre-funded warrants to purchase an aggregate of 4,475,000 shares of common stock, and common warrants to purchase up to an aggregate of 10,000,000 shares of common stock. Each share of common stock or pre-funded warrant, as applicable, is being sold together with a common warrant to purchase one share of common stock at a combined effective price to the public of $0.80 per share and accompanying common warrant.

H.C. Wainwright & Co., LLC is acting as the sole book-running manager for the offering.

The common warrants will be exercisable immediately at an exercise price of $0.80 per share and will expire five years from the date of issuance. The shares of common stock or pre-funded warrants, as applicable, and the accompanying common warrants can only be purchased together in this offering but will be issued separately. This offering is expected to close on or about November 3, 2017, subject to customary closing conditions.

In addition, Eleven has granted the underwriter a 30-day option to purchase up to 1,500,000 additional shares of common stock at a purchase price of $0.79 per share and/or common warrants to purchase up to an aggregate of 1,500,000 shares of common stock at a purchase price of $0.01 per common warrant with an exercise price of $0.80 per share to cover over-allotments, if any, less the underwriting discounts and commissions.

The gross proceeds of the offering are expected to be approximately $8.0 million, prior to deducting underwriting discounts and commissions and estimated offering expenses.

Eleven intends to use the net proceeds from this offering to continue to fund the clinical development of its lead product candidate Vicinium and for general corporate purposes, which may include capital expenditures and funding its working capital  

CAMBRIDGE,  Mass.,  November  3,  2017  –  Eleven  Biotherapeutics,  Inc.  (“Eleven”  or  the  “Company”)  (NASDAQ:EBIO),  a  late-stage  clinical
oncology company advancing novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today announced the closing of
the previously announced underwritten public offering of 5,525,000 shares of its common stock, pre-funded warrants to purchase an aggregate of
4,475,000  shares  of  common  stock,  and  common  warrants  to  purchase  up  to  an  aggregate  of  10,000,000  shares  of  common  stock.  Each  share  of
common stock or pre-funded warrant, as applicable, was sold together with a common warrant to purchase one share of common stock at a combined
effective price to the public of $0.80 per share and accompanying common warrant.
H.C. Wainwright & Co., LLC acted as the sole book-running manager for the offering.
The gross proceeds of the offering were approximately $8.0 million and the net proceeds from the offering were approximately $7.0 million, after
deducting underwriting discounts and commissions and other offering expenses. Eleven intends to use the net proceeds from this offering to continue
to fund the clinical development of its lead product candidate Vicinium and for general corporate purposes, which may include capital expenditures
and funding its working capital needs.
The common warrants issued in the offering are exercisable immediately at an exercise price of $0.80 per share and will expire five years from the
date of issuance. The pre-funded warrants are exercisable immediately at an exercise price of $0.01 per share and may be exercised until they are
exercised  in  full.  The  shares  of  common  stock  or  pre-funded  warrants,  as  applicable,  and  the  accompanying  common  warrants  could  only  be
purchased together in the offering but were subsequently issued separately.
In addition, Eleven has granted the underwriter a 30-day option to purchase up to 1,500,000 additional shares of common stock at a purchase price of
$0.79  per  share  and/or  common  warrants  to  purchase  up  to  an  aggregate  of  1,500,000  shares  of  common  stock  at  a  purchase  price  of  $0.01  per
common warrant with an exercise price of $0.80 per share to cover over-allotments, if any, less the underwriting discounts and commissions.
A  registration  statement  on  Form  S-1  (File  No.  333-
220809)  relating  to  these  securities  was  declared  effective  by  the  Securities  and  Exchange
Commission (SEC) on November 1, 2017. The offering was made only by means of a prospectus forming part of the effective registration statement.
A final prospectus relating to and describing the terms of the offering has been filed with the SEC. Copies of the final prospectus relating to the
offering may be obtained for free by visiting the SEC's website at www.sec.gov or from H.C. Wainwright & Co., LLC, 430 Park Avenue, 4th Floor,
New York, New York 10022, by email at placements@hcwco.com or by telephone at 646-975-6996.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities
in  any  state  or  other  jurisdiction  in  which  such  offer,  solicitation  or  sale  would  be  unlawful  prior  to  the  registration  or  qualification  under  the
securities laws of any such state or other jurisdiction.
About Eleven Biotherapeutics
Eleven  Biotherapeutics,  Inc.  is  a  late-stage,  clinical  oncology  company  advancing  novel  product  candidates  based  upon  the  Company’s  targeted
protein therapeutics (TPTs) platform. The Company’s TPTs incorporate a tumor-targeting antibody fragment and a protein cytotoxic payload into a
single  protein  molecule  in  order  to  achieve  focused  tumor  cell  killing.  The  Company  believes  its  TPT  approach  offers  significant  advantages  in
treating cancer over existing antibody drug conjugate technologies. The Company believes its TPTs provide effective tumor targeting with broader
cancer  cell-killing  properties  than  are  achievable  with  small  molecule  payloads  that  require  tumor  cell  proliferation  and  face  multi-drug  resistant
mechanisms. Additionally,  the  Company  believes  that  its  TPT’s  cancer  cell-killing  properties  promote  an  anti-tumor  immune  response  that  will
potentially combine well with immune oncology drugs such as checkpoint inhibitors. For more information, please refer to the Company’s website at
www.elevenbio.com
.
 

ob es dann wieder  hoch geht.  

und wie ist deine Meinung zu Eleven ?  

veröffentlicht.  

For the three months ended September 30, 2017, the Company expects to report that there was no revenue compared to $28.7 million in revenue for the three
months ended September 30, 2016. In August 2016, the Company recognized the upfront license fee and the development milestone payment under its
license agreement (the “License Agreement”) with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (collectively, “Roche”), relating to the execution
of the License Agreement and the successful submission of an investigation new drug application for its monoclonal antibody EBI-031.
The Company also expects to report that general and administrative expenses were $1.6 million for the three months ended September 30, 2017 compared to
$6.4 million for the three months ended September 30, 2016. The decrease of $4.8 million was due primarily to a reduction in professional fees as well as
salaries and related costs for personnel, including stock-based compensation. For the three months ended September 30, 2016, the Company had higher
professional fees compared to the 2017 period related to the License Agreement with Roche, its 2016 review of strategic alternatives and its acquisition of
Viventia in September 2016. In addition, for the three months ended September 30, 2016, the Company paid higher severance costs related to its acquisition
of Viventia compared to the 2017 period.
The Company expects to report that research and development expenses for the three months ended September 30, 2017 were $3.6 million as compared to
$2.8 million for the three months ended September 30, 2016. This increase was due primarily to higher costs incurred for the Company’s ongoing Phase 3
clinical trial for Vicinium in patients with non-muscle invasive bladder cancer that were partially offset by the absence of costs associated with the
monoclonal antibody EBI-031licensed to Roche in 2016 and lower compensation related costs.
As reference above in Part III, the Company intends to make certain acquisition accounting adjustments in its financial statements in connection with
finalization of the accounting for the acquisition of Viventia, as well as the fair value of the contingent consideration liability as of September 30, 2017, all
of which have not yet been completed.
A reasonable estimate of the results of operations for the Company for the three months ended September 30, 2017
cannot be made until all accounting relating to the acquisition of Viventia and the estimate of the fair value of the contingent consideration as of September
30, 2017 have been finalized, and we have completed preparation of financial statements for inclusion in the Form 10-Q.
 

und geht es jetzt wieder hoch.  

http://www.nasdaq.com/de/symbol/ebio/real-time  

Eleven  

bei hohe Umsätze, das ist schon mal gut.